# Shenzhen Zhongke Xinjin Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-zhongke-xinjin-biotechnology

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Total disclosed funding: $1.6M
- Latest round: Angel (Nov 26, 2021)
- Investors on record: 4

## About

Based in Shenzhen, China, and established in 2021, Shenzhen Zhongke Xinjin Biotechnology is a peptide drugs developer. The company co-found by Professor Peigen Ren, an expert from the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, and Mr. Liangzheng Qin, who is engaged in the development and production of peptide drug technology.

The company developed two product lines, Non-alcoholic steatohepatitis (NASH) and lose weight. Those products used the technology of Metabolitin -GPRC6A-Neurotensin inhibiting the absorption of lipids in the small intestine, and MTL-GPRC6A-GLP-1 regulating blood sugar.

The company plans to accelerate the development of the NASH, and lose weight drug, and to complete to apply for investigational new drug (IND) of National Medical Products Administration (NMPA), and Food and Drug Administration (FDA) in 2024. Moreover, it will continue to develop new drug for metabolic diseases and reproductive health.

## Funding rounds

- Angel, Nov 26, 2021, $1.6M — ASB Ventures, Greatwall Fund, Nanshan Venture Capital, Shenzhen Fupeng Asset Management Co., LTD

## Investors

- ASB Ventures (https://capitalatlas.ai/funds/asb-ventures) — Angel
- Greatwall Fund (https://capitalatlas.ai/funds/greatwall-fund) — Angel
- Nanshan Venture Capital (https://capitalatlas.ai/funds/nanshan-venture-capital) — Angel
- Shenzhen Fupeng Asset Management Co., LTD — Angel